Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer

Katalin Boér
Department of Medical Oncology, Szent Margit Hospital, Budapest, Hungary

Abstract: Breast cancer is a heterogeneous disease with multiple subgroups based on clinical and molecular characteristics. For the largest subgroup of breast cancers, hormone receptor-positive/human epidermal growth factor 2 (HER2)-negative tumors, hormone treatment is the mainstay of therapy and is likely to result in significant improvement in disease outcomes. However, some of these cancers demonstrate de novo or acquired resistance to endocrine therapy. Despite intensive research to develop new strategies to enhance the efficacy of currently available treatment options for hormone receptor-positive breast cancer, progress has been slow, and there were few advances for a period of 10 years. In 2012, a new molecularly targeted therapeutic strategy, inhibition of mammalian target of rapamycin with everolimus, was introduced into clinical practice. Everolimus, in combination with a steroidal aromatase inhibitor, exemestane, resulted in an increase in progression-free survival, but not overall survival in patients with estrogen receptor (ER)+ve advanced disease who had progressed on hormone therapy. In 2015, the first cyclin-dependent kinases 4/6 (CDK4/6) inhibitor, palbociclib, received accelerated US Food and Drug Administration approval for use in combination with letrozole for the treatment of postmenopausal ER+ve/HER2−ve advanced breast cancer as initial, endocrine-based therapy. The addition of palbociclib to endocrine therapy resulted in longer progression-free survival than letrozole alone. One year later, palbociclib received a new indication, use in combination with fulvestrant, in both premenopausal and postmenopausal females with advanced breast cancer of the same subtype with disease progression following endocrine therapy. Adding palbociclib to fulvestrant resulted in a significantly increased median progression-free survival compared to fulvestrant monotherapy. These new combination regimens of palbociclib with endocrine agents represent an important addition to the therapeutic armamentarium in ER+ve/HER2−ve advanced and metastatic breast cancer.

Keywords: breast cancer, endocrine treatment, CDK4/6 inhibitor, palbociclib

Introduction
Breast cancer is a heterogeneous disease, with multiple molecular profiles. Tumors can be classified according to the expression of the estrogen receptor (ER), progesterone receptor, and human epidermal growth factor 2 (HER2, also known as HER2/neu) receptor status into HER2+ve, ER+ve/HER2−ve, and triple-negative clinical subtypes.1 ER is expressed in ~70% of all breast cancers and endocrine therapies are the mainstay of treatment for these tumors.2

According to guidelines, hormone therapy is a major therapeutic option in locally advanced and metastatic ER+ve/HER2−ve breast cancer. Sequential hormone therapy (alone or in combination) should be used as initial treatment, except in cases...
of immediately life-threatening disease, or with extensive visceral or symptomatic metastases. Until recently, the only hormonal strategies in clinical use were tamoxifen, aromatase inhibitors, and fulvestrant used alone. Even though endocrine therapy is the most effective treatment for ER+/HER2− tumors, up to a quarter may show de novo resistance to hormone therapies or acquired resistance during the course of disease. For this reason, efforts have been made to identify new therapeutic strategies to overcome endocrine resistance and to enhance the efficacy of endocrine treatments by combining hormone therapy with other targeted treatment approaches, such as small-molecule inhibitors. In this context, targeting the mammalian target of rapamycin with everolimus in combination with exemestane resulted in improving progression-free survival (PFS) in patients with hormone receptor (HR)+ve breast cancer who had progressed on an aromatase inhibitor. In addition, data from several clinical trials suggest that inhibitors of the cyclin-dependent kinases 4 and 6 (CDK4/6) are also able to delay or reverse resistance to endocrine therapy. The first-in-class CDK4/6 inhibitor, palbociclib, has been introduced into clinical practice in 2015 for the treatment of ER+/HER2− locally advanced or metastatic breast cancer.

Inhibition of CDK4/6

The cell cycle is driven by an interplay between cyclins and their associated cyclin-dependent kinases, a family of serine/threonine kinases that interact with cyclins, and have an important role in cell division. Despite the large number of CDKs and cyclins, only a few have been strongly implicated in breast cancer pathogenesis. Oncogenic signals in HR+ve breast cancer promote expression of cyclin D1 and activate CDK4/CDK6, which could result in breast cancer proliferation. Newly synthesized cyclin D1 forms activating complexes with CDK4/6, which initiate phosphorylation of retinoblastoma gene product (pRb). The cyclin D-CDK4/6-Rb pathway, which is downstream of many mitogenic cascades, controls the cell cycle restriction point and is commonly dysregulated in breast carcinoma. This pathway became an important target for drug development and its alteration can occur by different mechanisms, such as CDK mutations, inactivation of p16, and overexpression of the cyclin D1 gene. In ER+ve breast cancer, both steroid and peptide growth factors drive proliferation through cyclin D-CDK4/6 activation, which results in the hyperphosphorylation of pRb. In the presence of hyperphosphorylated pRb, the transcription factor E2 (E2F) is released and the cell progresses through the S phase of the cycle (Figure 1). Small-molecule inhibitors of CDK4/6 block the hyperphosphorylation of pRb and cause G1 cell cycle arrest. Greater knowledge of the interplay between the steroid hormone pathway, peptide growth factor signaling, and CDK biology is likely to broaden our understanding of the mechanisms of endocrine resistance.

Therapeutic CDK4/6 inhibition in breast cancer

In early studies, the first-generation of less selective CDK inhibitors, such as flavopiridol and seliciclib showed minimal activity and had several dose-limiting toxicities, including unacceptably high rates of neutropenia, hyperglycemia, cardiac, and pulmonary dysfunction. Recently, small-molecule inhibitors specific for CDK4/6 have entered clinical testing. Currently, three oral selective CDK4/6 inhibitors are at different stages of clinical development: palbociclib (PD-0332991), ribociclib (LEE011), and...
Palbociclib: preclinical data

Palbociclib (PD-0332991) is an orally bioavailable CDK4/6 inhibitor with IC50 of 0.01 μM in vitro and high selectivity for CDK4/6 compared with other CDKs. In preclinical studies, palbociclib has been shown to target CDK4/6 specifically, with potent inhibition of tumor cell proliferation by G1 arrest, leading to dephosphorylation of pRb, a decrease of E2F-dependent gene expression and potent inhibition of tumor cell proliferation through arrest in G1. Moreover, palbociclib is completely inactive in pRb-negative tumor cell lines and xenografts. The pioneering work of Finn et al documented the activity of palbociclib in reducing proliferation of ER+ve breast cancer cell lines by blocking the progression of cells from G1 into the S phase of the cell cycle. They also showed that ER+ve or HER2-amplified cell lines subtypes were most sensitive to palbociclib inhibition while cell lines from other nonluminal subtypes were most resistant. In addition, synergy was demonstrated between palbociclib and tamoxifen in growth inhibition and the drug showed activity in a model of acquired tamoxifen resistance.7,18

Clinical efficacy of palbociclib in combination with hormone therapy

Palbociclib in combination with letrozole as initial endocrine-based therapy

Palbociclib in combination with letrozole received accelerated US Food and Drug Administration approval in February 2015, as initial therapy for postmenopausal females with HR+ve/HER2−ve advanced breast cancer, based on the very favorable PFS results of PALOMA 1 clinical trial. PALOMA-1 (NCT00721409) was a randomized, multicentre, Phase I/II study, in which postmenopausal patients with HR+ve/HER2−ve advanced breast cancer received either the combination of palbociclib and letrozole, or letrozole alone. A total of 165 postmenopausal females with stage IV breast cancer or inoperable locally recurrent disease who had not received any systemic treatment for advanced disease were enrolled in the trial. In the combination arm, treatment consisted of palbociclib 125 mg/day for 21 consecutive days followed by 7 days off treatment and letrozole 2.5 mg/day continuously. Initially, the study consisted of two parts: in part I enrollment was based on HR and HER2 status alone and the efficacy, safety, and tolerability of the

---

**Table 1 Phase II/III clinical studies with CDK4/6 inhibitors in breast cancer**

<table>
<thead>
<tr>
<th>Clinical trial</th>
<th>Trial setting</th>
<th>Primary endpoint</th>
<th>Combination</th>
<th>N</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abemaciclib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>neoMONARCH</td>
<td>Neoadjuvant</td>
<td>Biomarker</td>
<td>Anastrozole</td>
<td>220</td>
<td>II</td>
</tr>
<tr>
<td>MONARCH-1</td>
<td>Metastatic</td>
<td>Response</td>
<td>Single agent</td>
<td>128</td>
<td>II</td>
</tr>
<tr>
<td>MONARCH-2</td>
<td>Metastatic</td>
<td>PFS</td>
<td>Fulvestrant</td>
<td>630</td>
<td>III</td>
</tr>
<tr>
<td>MONARCH-3</td>
<td>Metastatic</td>
<td>PFS</td>
<td>Nonsteroidal AI</td>
<td>450</td>
<td>III</td>
</tr>
<tr>
<td>NCT02308020</td>
<td>Brain metastasis</td>
<td>Response</td>
<td>Single agent</td>
<td>120</td>
<td>II</td>
</tr>
<tr>
<td>Ribociclib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MONALEESA-1</td>
<td>Neoadjuvant</td>
<td>Pharmacodynamic</td>
<td>Letrozole</td>
<td>120</td>
<td>II</td>
</tr>
<tr>
<td>MONALEESA-2</td>
<td>Metastatic</td>
<td>PFS</td>
<td>Letrozole</td>
<td>650</td>
<td>III</td>
</tr>
<tr>
<td>MONALEESA-3</td>
<td>Metastatic</td>
<td>PFS</td>
<td>Fulvestrant</td>
<td>660</td>
<td>III</td>
</tr>
<tr>
<td>MONALEESA-7</td>
<td>Metastatic</td>
<td>PFS</td>
<td>Tamoxifen</td>
<td>660</td>
<td>III</td>
</tr>
<tr>
<td>(premenopausal)</td>
<td></td>
<td></td>
<td>Non-steroidal AI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Palbociclib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PALOMA-1/TRIO-18</td>
<td>Metastatic</td>
<td>PFS</td>
<td>Letrozole</td>
<td>165</td>
<td>II</td>
</tr>
<tr>
<td>PALOMA-2</td>
<td>Metastatic</td>
<td>PFS</td>
<td>Letrozole</td>
<td>450</td>
<td>III</td>
</tr>
<tr>
<td>PALOMA-3</td>
<td>Metastatic</td>
<td>PFS</td>
<td>Fulvestrant</td>
<td>417</td>
<td>III</td>
</tr>
<tr>
<td>PALOMA-4</td>
<td>Metastatic</td>
<td>PFS</td>
<td>Letrozole</td>
<td>330</td>
<td>III</td>
</tr>
<tr>
<td>PEARL</td>
<td>Metastatic</td>
<td>PFS</td>
<td>Exemestane vs capecitabine</td>
<td>348</td>
<td>III</td>
</tr>
<tr>
<td>PENELlope-B</td>
<td>High risk adjuvant</td>
<td>idDFS</td>
<td>Antihormonal</td>
<td>800</td>
<td>III</td>
</tr>
<tr>
<td>PALLet</td>
<td>Neoadjuvant</td>
<td>Biomarker cCR</td>
<td>Letrozole</td>
<td>306</td>
<td>II</td>
</tr>
<tr>
<td>PARSIFAL</td>
<td>Metastatic</td>
<td>PFS</td>
<td>Letrozol or Fulvestrant</td>
<td>304</td>
<td>III</td>
</tr>
<tr>
<td>FLIPPER</td>
<td>Metastatic</td>
<td>PFS</td>
<td>Letrozol or Fulvestrant</td>
<td>190</td>
<td>II</td>
</tr>
<tr>
<td>PALLAS</td>
<td>Adjuvant</td>
<td>idDFS</td>
<td>Antihormonal</td>
<td>4,600</td>
<td>III</td>
</tr>
<tr>
<td>NeoPAL</td>
<td>Neoadjuvant</td>
<td>RCB</td>
<td>Letrozole vs FEC-3</td>
<td>306</td>
<td>II</td>
</tr>
</tbody>
</table>

Abbreviations: AI, aromatase inhibitor; CDK, cyclin D-cyclin-dependent kinase; cCR, clinical complete response, FEC, fluorouracil, epirubicin, cyclophosphamide; idDFS, invasive disease-free interval; N, number of patients; PFS, progression-free survival; RCB, residual cancer burden.

abemaciclib (LY2835219). Of these, palbociclib is the most advanced in development (Table 1).
Palbociclib in combination with fulvestrant following endocrine therapy

Food and Drug Administration approval of palbociclib was extended in February 2016, when the drug received a new indication for use in combination with fulvestrant, based on the results of the PALOMA-3 (NCT01942135) clinical trial. In this Phase III study, patients were randomized to receive palbociclib (125 mg/day orally for 21 days, followed by 7 days off) and fulvestrant (500 mg intramuscularly every 14 days for the first three injections and then every 28 days) or placebo and fulvestrant. In contrast to PALOMA-1, premenopausal or perimenopausal patients were also eligible; they received goserelin for the duration of study treatment. PALOMA-3 was terminated early, when the primary endpoint had been met at the preplanned interim analysis. The final PFS was 9.5 months in the group treated with the combination of palbociclib and fulvestrant, and 4.6 months with placebo-fulvestrant (hazard ratio 0.46; 95% CI 0.36–0.59; P<0.0001). The PFS results were consistent in subgroup analyses, across various demographic and prognostic factors. Moreover, the relative difference in PFS between palbociclib and placebo was similar in premenopausal, perimenopausal, and postmenopausal patients. The overall objective response rates were 10.4% with palbociclib–fulvestrant and 6.3% with placebo–fulvestrant (P=0.16). The rate of clinical benefit, defined as response or prolonged stable disease, was higher with the combination of palbociclib and endocrine therapy than with placebo–fulvestrant (34.0% vs 19.0%, P<0.001). At the time of the first interim analysis, the OS data were immature.

Palbociclib safety profile: adverse events of special interest

In two, randomized, international studies (PALOMA-1 and PALOMA-3) palbociclib in combination with endocrine therapy (letrozole or fulvestrant) was an effective and well-tolerated treatment for patients with advanced ER+ve/HER2–ve breast cancer, with manageable toxicity. In both studies, adverse events of special interest were neutropenia (75% vs 5%), leukopenia (43% vs 3%), fatigue (41% vs 23%), and anemia (35% vs 7%). Neutropenia was reported in 75% of patients in PALOMA-1, whereas this side-effect occurred in 83% of cases in PALOMA-3. Despite the high rate of leukopenia and neutropenia, febrile neutropenia was reported in only ~1% of patients exposed to palbociclib, and did not lead to serious clinical consequences. Neutropenia is believed to be due to the cytostatic effect of palbociclib on bone marrow progenitor cells. According to the product label, complete blood counts are required prior to starting palbociclib therapy, at the beginning of each cycle, on day 14 of the first two cycles, then as clinically indicated. For patients developing grade 3 or 4 neutropenia, dose interruption, dose reduction, or delay in starting subsequent treatment cycles is recommended.

Future directions: palbociclib in early-stage breast cancer

Based on the therapeutic advantage observed with the addition of palbociclib to hormone therapy in metastatic breast cancer, evaluation in early-stage breast disease is a logical next step. Currently, two large Phase III studies, PENEO-PE-B and PALLAS, are ongoing, evaluating the feasibility of adding palbociclib to hormone therapy as adjuvant treatment in early breast cancer. Two other clinical trials (PALLE and NeoPal) have been designed to evaluate the role of CDK4/6 inhibition with palbociclib as neoadjuvant treatment.

Expert opinion

Despite advances in the treatment of ER+ve/HER2–ve breast cancer, there is a high incidence of recurrence and progression on available standard therapies. Personalizing the use of anticancer treatments is a major focus in clinical
practice. Deregulation of the cyclin D-CDK4/6-Rb pathway is commonly seen in ER+ve breast cancer and this observation led to the identification of CDK4/6 as an attractive new target for treatment. The development of CDK4/6 inhibitors and the introduction of palbociclib, the first in this class, into clinical practice, represent an important addition to the therapeutic armamentarium in metastatic breast cancer.

Adding palbociclib to endocrine therapy significantly extended PFS in comparison with endocrine therapy in the first and subsequent lines of treatment for ER+ve/HER2-ve advanced and metastatic breast cancer. Moreover, palbociclib has shown a consistent clinical efficacy and safety profile in combination with letrozole or fulvestrant in this subtype of breast cancer. In first-line treatment in postmenopausal advanced breast cancer, the addition of palbociclib to letrozole was associated with significantly longer PFS than letrozole alone (20.2 vs 10.2 months). In addition, the combination of palbociclib and fulvestrant resulted in a significantly longer PFS (9.5 vs 4.6 months) compared with fulvestrant alone when used in later lines of treatment in both pre- and postmenopausal patients who had progressed on previous endocrine therapy. Recently, the primary results of a confirmatory Phase III trial, PALOMA-2, were presented; these expand and confirm the significant clinical benefit and safety of the palbociclib–letrozole combination in ER+ve/HER2-ve advanced breast cancer. OS data are not yet available or mature, but the clinically relevant activity of palbociclib resulting in more than doubling of the PFS is sufficient for it to be used in patients carefully selected based on clinical characteristics to identify those who are likely to benefit most. In addition, the observed PFS prolongation raises the possibility of improvement in OS, which could ultimately lead to ER+ve/HER2-ve advanced breast cancer becoming a chronic disease. The results of PALOMA-1 support the preclinical observation that ER positivity is the best biomarker so far to select patients likely to benefit from CDK4/6 inhibition. Overall, the combination of palbociclib and endocrine therapy is a well-tolerated treatment, with leukopenia and neutropenia being the most common side-effects.

There are several therapeutic choices available for ER+ve/HER2-ve advanced breast cancer, but adding palbociclib to hormone therapy is an option with strong efficacy data. Moreover, at present, based on the remarkable PFS prolongation the combination of palbociclib and hormone therapy can be used in well-selected patients to delay the need to initiate cytotoxic chemotherapy.

Two other CDK4/6 inhibitors, ribociclib and abemaciclib, are in clinical development with ongoing clinical trials in similar combinations and indications, as well as other indications. CDK4/6 inhibitors may have a role in the adjuvant setting due to their good clinical activity and the low, tolerable, and predictable side effects. Studies are also ongoing to evaluate CDK4/6 inhibitors as neoadjuvant and adjuvant treatment. There are several open questions about the role of CDK4/6 inhibitors in daily practice, such as the increased treatment costs, the optimal place in the treatment continuum, and identification of predictive markers for routine patient selection.

Disclosure

The author has received consulting fees from GlaxoSmithKline, Novartis, Pfizer, and Roche.

References


38. Finn RS, Martin M, Rugo HS, et al. PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/-HER2− advanced breast cancer (ABC). J Clin Oncol. 2016;34 suppl; abstr 507.


40. A randomized, double-blind, parallel-group, multicentre, phase ii study to compare the efficacy and tolerability of fulvestrant (faslodextm) 500 mg with placebo and fulvestrant (faslodextm) 500 mg in combination with PD-0332991 (Palbociclib) as first line treatment for postmenopausal women with hormone receptor-positive metastatic breast cancer, who have completed at least 5 years of adjuvant endocrine therapy and remained disease free for more than 12 months following its completion or have “de novo” metastatic disease. “The FLIPPER Study”. Available from: https://clinicaltrials.gov/ct2/show/NCT02690480. NLM identifier: NCT02690480. Accessed August 15, 2016.